10x Genomics, Inc. - 8-K Filing
10x Genomics reported Q1 2026 revenue of $150.8 million, a 3% decrease from $154.9 million in Q1 2025, but a 9% increase excluding $16.8 million in one-time revenue from 2025. Gross margin improved to 70% from 68% year-over-year. The company launched its Atera platform and announced a partnership with Bioptimus. It maintained full-year 2026 revenue guidance of $600 million to $625 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $TXG